A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study
Manish K. Thakur, Lance K. Heilbrun, Shijie Sheng, Mark Stein, Glenn Liu, Emmanuel S. Antonarakis, Ulka Vaishampayan, Sijana H. Dzinic, Xiaohua Li, Stacy Freeman, Daryn Smith, Elisabeth I. Heath
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study'. Together they form a unique fingerprint.